Sandoz’s Carol Lynch elected to chair European Biosimilars Group
pharmafile | February 10, 2016 | Appointment | Medical Communications | biosimilars
The European Generic Medicines Association (EGA) has elected Carol Lynch, global head of Biopharmaceuticals & Oncology Injectables at Sandoz, as chair of its European Biosimilars Group (EBG).
The European Biosimilars Group (EBG), a sector group of the EGA, represents the leading companies in the biosimilar medicines space.
In this new role, Lynch, along with fellow EBG members, will support the expansion of patient access to high-quality biosimilar medicines, while ensuring the sustainability of the industry. Lynch named three priorities for the industry to focus on with regard to biosimilars, under her tenure, for the next two years:
- Increasing stakeholder awareness and understanding through education
- Strengthening regulatory and scientific concepts
- Advocating for industrial policies that supports growth of the biosimilars industry
Commenting on her new role, Lynch says: “The EBG has made tremendous progress in strengthening the impact of biosimilars in Europe. As the newly elected chair, I look forward to representing the EBG during what promises to be another important two years for all biosimilar stakeholders.”
At Sandoz, the generics arm of Novartis, Lynch leads a 3000+ person organisation focused on the development, manufacturing and commercialisation of biosimilars and oncology injectables. She is also responsible for Sandoz’s biopharmaceutical contract manufacturing business.
Lynch has more than 25 years of global pharmaceutical and generics industry experience. Prior to joining Sandoz in 2014, she held several commercial and development leadership positions in Novartis Pharmaceuticals both globally and in country organisations, including the US. She is a member of the Sandoz Executive Committee, and chair of the European Biosimilars Group.
Related Content
Samsung Bioepis & Biogen receive positive CHMP opinion for ranibizumab biosimilar
Samsung Bioepis and Biogen have announced that the EMA’s Committee for Medicinal Products for Human …
Biosimilars and Brexit: What’s in store for UK’s biosimilar market?
It’s been 15 years since the first biosimilar entered the market, and the impact of …
Exclusive interview: Samsung Bioepis’ Sang-Jin Pak on the rise of biosimilars
Following on from our focus on biosimilars in our feature last week, you can read …
